[HTML][HTML] … based on baseline concomitant mutations and longitudinal circulating tumor DNA monitoring in advanced EGFR-mutant lung adenocarcinoma under gefitinib …
J Duan, JC Xu, Z Wang, H Bai, Y Cheng, T An… - Journal of Thoracic …, 2020 - Elsevier
… osimertinib as compared with gefitinib and erlotinib, leading to the … to guide first-line gefitinib
in patients with metastatic lung … analysis of the BENEFIT cohort by further tracking the ctDNA …
in patients with metastatic lung … analysis of the BENEFIT cohort by further tracking the ctDNA …
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study
Q Zhou, CR Xu, Y Cheng, YP Liu, GY Chen, JW Cui… - Cancer cell, 2021 - cell.com
… This phase 3 study investigated the efficacy and safety of an erlotinib plus bevacizumab …
In total, 311 patients received bevacizumab plus erlotinib (n = 157) or erlotinib only (n = 154). …
In total, 311 patients received bevacizumab plus erlotinib (n = 157) or erlotinib only (n = 154). …
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
… studies, patients received erlotinib or gefitinib, with similar overall survival (OS) between
groups (no statistically significant differences). One study … A recent large cohort study of patients …
groups (no statistically significant differences). One study … A recent large cohort study of patients …
Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of …
HC Chang, KT Huang, CC Tseng, YM Chen… - Thoracic …, 2023 - Wiley Online Library
… cohorts were from Taiwan (n = 5940) and Japan (n = 1366). All included studies compared
afatinib with gefitinib and erlotinib. … studies for gefitinib, eight for afatinib, and four for erlotinib. …
afatinib with gefitinib and erlotinib. … studies for gefitinib, eight for afatinib, and four for erlotinib. …
[HTML][HTML] A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer
Q Zhao, K Sun, X Lei, L Cai - Medicine, 2020 - journals.lww.com
… Existing studies … gefitinib or erlotinib is used alone to treat patients with EGFR mutations.
[3] However, with the treatment prolonged, especially after over 9 months, gefitinib or erlotinib …
[3] However, with the treatment prolonged, especially after over 9 months, gefitinib or erlotinib …
[HTML][HTML] … of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival …
B Zhao, Y Wang, Y Wang, W Chen, L Zhou… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
… EGFI-TKI here included 250 mg/d gefitinib or 150 mg/d erlotinib. § These previous definitive
treatment or glucocorticoid therapy had to be completed at least two weeks before launching …
treatment or glucocorticoid therapy had to be completed at least two weeks before launching …
[HTML][HTML] Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
… survival (OS) advantage over gefitinib/erlotinib in this study [7], thus … does not improve OS
versus gefitinib/erlotinib in Asia and, in … For example, a cohort study (n = 67) that utilized liquid …
versus gefitinib/erlotinib in Asia and, in … For example, a cohort study (n = 67) that utilized liquid …
First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
… In the current study, however, we compared afatinib to pooled data for gefitinib and erlotinib.
Second, in this study, the patients who received afatinib had better performance statuses …
Second, in this study, the patients who received afatinib had better performance statuses …
… Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
DF Chamorro, AF Cardona, J Rodríguez… - Targeted Oncology, 2023 - Springer
… an increased affinity for first-generation (ie, gefitinib, erlotinib, and icotinib), second-generation
(… Previous evidence suggested that gefitinib combined with the BH3 mimetic ABT-737 (an …
(… Previous evidence suggested that gefitinib combined with the BH3 mimetic ABT-737 (an …
A prospective cohort study assessing the relationship between plasma levels of Osimertinib and Treatment Efficacy and Safety
T Fukuhara, K Imai, T Nakagawa, R Igusa, H Yokota… - Biomedicines, 2023 - mdpi.com
… Previous studies have reported a positive association between trough levels of gefitinib,
erlotinib or afatinib and several adverse events [6,7]. Conversely, in some reports, the …
erlotinib or afatinib and several adverse events [6,7]. Conversely, in some reports, the …